An E7-based therapeutic vaccine protects mice against HPV16 associated cancer

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3395-3397

  Venuti, Aldo ^a   Massa, Silvia ^b,c   Mett, Vadim ^c   Vedova, Laura Dalla ^a   Paolini, Francesca ^a   Franconi, Rosella ^b   Yusibov, Vidadi ^c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ENEA   (Italy)

^c UNIVERSITY OF DELAWARE   (United States)

Author keywords

Cancer vaccine; Human papilloma virus; Plant produced vaccine

Indexed keywords

CANCER VACCINE; GLUCAN GLUCOSIDASE; LICKM E7GGG VACCINE; PROTEIN E7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CLOSTRIDIUM THERMOCELLUM; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG PURIFICATION; DRUG SYNTHESIS; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NICOTIANA BENTHAMIANA; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TOBACCO; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANIMALS; FEMALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TOBACCO; VACCINATION; VACCINES, SYNTHETIC;

EID: 67349204308     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.068     Document Type: Article

References (13)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 6 (1999) 827-841
2. Zur Hausen. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350
3. Zur Hausen. Perspectives of contemporary papillomavirus research. Vaccine 24 Suppl. 3 (2006) iii-iv
4. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 90. Human papillomavirus (2005), WHO Press, Geneva, Switzerland
5. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 11 (1995) 796-802
6. Fehrmann F., and Laimins L.A. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22 33 (2003) 5201-5207
7. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
8. Gerard C.M., Baudson N., Kraemer K., Bruck C., Garcon N., Paterson Y., et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19 17-19 (2001) 2583-2589
9. Massa S., Franconi R., Brandi R., Muller A., Mett V., Yusibov V., et al. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25 April (16) (2007) 3018-3021
10. Smahel M., Sima P., Ludvikova V., and Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281 2 (2001) 231-238
11. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
12. Eiben G.L., Velders M.P., and Kast W.M. The cell mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res 86 (2002) 113-148
13. Tindle W.R. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2 (2002) 59-65